CRISPR Therapeutics registers Phase 1/2 trial of CTX340 for treatment-resistant hypertensionAug 11Trial updateCRISPR Therapeutics AGCTX340
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial startsAug 3Quarterly updateCRISPR Therapeutics AGCTX340
Sign inSign in